Ebola vs Marburg Virus: Key Differences, Similarities, and Why Both Are Dangerous
A detailed comparison of Ebola and Marburg viruses — two filoviruses with similar clinical presentations but important epidemiological differences. Covers CFR, transmission, outbreaks, and vaccines.
Both Are Filoviruses — But They Are Distinct Viruses
Ebola and Marburg are often discussed together, and for good reason: they are both members of the family Filoviridae, both cause severe viral hemorrhagic fever, both originate in Africa, and both have case fatality rates among the highest of any human pathogen. But they are caused by different viruses in different genera, and understanding their differences is important for public health response.
| Feature | Ebola | Marburg |
|---|---|---|
| Genus | Ebolavirus | Marburgvirus |
| Species | 6 (Zaire, Sudan, Bundibugyo, Tai Forest, Reston, Bombali) | 1 (Marburg virus, including Ravn variant) |
| First identified | 1976, Yambuku, DRC | 1967, Marburg/Frankfurt, Germany |
| Natural reservoir | Fruit bats (Pteropodidae) | Egyptian fruit bat (Rousettus aegyptiacus) |
| CFR range | 25–90% | 24–88% |
| Approved vaccine | Yes (Ervebo for Zaire strain) | No (experimental candidates only) |
| Approved treatment | Yes (Inmazeb, Ebanga for Zaire strain) | No (experimental only) |
The Discovery Stories
Ebola (1976)
Ebola was discovered in September 1976 when two simultaneous outbreaks occurred — one in Yambuku, DRC (then Zaire), caused by the Zaire ebolavirus, and one in Nzara, Sudan (now South Sudan), caused by the Sudan ebolavirus. Belgian, Zairean, and American scientists identified the new filovirus and named it after the Ebola River near the Yambuku outbreak.
Marburg (1967)
Marburg virus was actually discovered before Ebola. In 1967, simultaneous outbreaks occurred in Marburg and Frankfurt, Germany, and in Belgrade, Yugoslavia. Workers at laboratories handling African green monkeys (Cercopithecus aethiops) imported from Uganda fell ill. 31 laboratory workers and contacts were infected; 7 died. The new virus was named after Marburg, Germany.
Clinical Comparison
Both diseases present with an initial non-specific febrile illness that can be confused with malaria or typhoid. The progression is similar:
Days 1–3: Sudden fever, severe headache, myalgia, extreme fatigue
Days 3–7: Gastrointestinal symptoms — nausea, vomiting, diarrhoea, abdominal pain. Rash (maculopapular) appears around day 5 in many patients.
Days 7–14: Escalation in severe cases — hemorrhagic manifestations (bleeding from multiple sites), neurological signs (encephalitis-like symptoms), renal failure, liver failure
Outcome: Death typically occurs around days 8–16 from multi-organ failure, septic shock, or hemorrhage. Survivors begin recovery after this period.
Key Clinical Differences
- Hemorrhage is somewhat more prominent in Marburg cases than in Ebola, with profuse bleeding from multiple sites being a more common terminal presentation
- Encephalitis (confusion, aggression) appears somewhat earlier in Marburg infection
- Rash appearance is similar but Ebola is more commonly described with a maculopapular rash across the trunk
Transmission: Essentially Identical
Both viruses spread through:
- Direct contact with the blood, vomit, faeces, or other body fluids of an infected symptomatic person
- Contact with the body of a deceased infected person (especially during funeral practices)
- Contaminated medical equipment (needles, syringes)
- Neither is airborne under normal circumstances
Sexual transmission has been documented for both — Ebola RNA persists in semen for up to 500+ days; Marburg has been documented in semen months after recovery.
Reservoir: Different Bat Species
Despite similarities, the two viruses use different reservoir species:
- Ebola: The primary natural reservoir for Zaire ebolavirus is believed to be Pteropodidae fruit bats (multiple species). Fruit bats can be infected with the virus without showing signs of disease.
- Marburg: The established natural reservoir is the Egyptian fruit bat (Rousettus aegyptiacus), which lives in large colonies in caves and mines across Africa. Multiple Marburg outbreaks have been traced to exposure in specific caves — including the Kitaka Cave in Uganda and the Magenta mine in Angola.
Outbreak Geography
Ebola
Ebola outbreaks are heavily concentrated in Central Africa (DRC, Republic of Congo, Gabon) and East Africa (Uganda, South Sudan). The West Africa epidemic (2014–2016) showed Ebola can spread to previously unaffected regions under the right conditions.
Marburg
Marburg outbreaks have been more sporadic but geographically diverse:
- Angola, 2004–2005: Largest Marburg outbreak, 252 cases, 90% CFR — the deadliest Marburg outbreak
- Uganda, 2007, 2012, 2017: Multiple outbreaks in miners with cave exposure
- Guinea, 2021: First confirmed Marburg in West Africa
- Ghana, 2022: Two cases, first in Ghana
- Tanzania, 2023: 9 cases, 6 deaths
- Rwanda, 2024: 66 cases, 15 deaths — significant outbreak in a stable country with no prior history
Vaccines and Treatments: The Gap
Ebola
- rVSV-ZEBOV (Ervebo): FDA- and EMA-approved for Zaire ebolavirus. Highly effective in ring vaccination.
- Ad26.ZEBOV/MVA-BN-Filo (Zabdeno/Mvabea): EU-approved two-dose regimen for stockpiling
- Treatments: Inmazeb and Ebanga are FDA-approved for Zaire ebolavirus
- Sudan ebolavirus: No approved vaccine or treatment — a critical gap
Marburg
- No approved vaccine as of 2026
- Multiple candidates in development: saRNA vaccine (Oxford), Ad26.MARV (Janssen/J&J), vesicular stomatitis virus-based (IAVI). Emergency use authorisation is being pursued for some candidates.
- No approved treatment for Marburg. Remdesivir and favipiravir are being investigated. Monoclonal antibodies are in early development.
The absence of approved Marburg countermeasures is a major gap in global health security, particularly given the 2024 Rwanda outbreak in a relatively stable, well-connected country.
Why Both Are Category A Bioterrorism Threats
Both Ebola and Marburg have been classified by the US CDC as Category A bioterrorism agents — the highest-priority category. This reflects their extreme lethality, potential for person-to-person spread, capacity to cause public panic, and requirement for special preparedness actions. Both viruses have been studied in former Soviet Union bioweapons programs (Biopreparat), though no weaponized agent has been confirmed in any outbreak.
The Bottom Line
Ebola and Marburg are the world’s two most feared hemorrhagic fever viruses. They share biological family, clinical presentation, and epidemiological dynamics — but differ in reservoir, geographic history, and (critically) the availability of countermeasures. The greater progress in Ebola vaccine and treatment development reflects the higher outbreak frequency of Ebola, which created both the demand and the clinical trial infrastructure to test interventions. Marburg’s less frequent outbreaks have historically provided fewer opportunities for clinical research — a vulnerability exposed by the 2024 Rwanda outbreak.